Edition:
United States

Sumitomo Dainippon Pharma Co Ltd (4506.T)

4506.T on Tokyo Stock Exchange

1,638JPY
12 Dec 2017
Change (% chg)

¥16 (+0.99%)
Prev Close
¥1,622
Open
¥1,621
Day's High
¥1,643
Day's Low
¥1,618
Volume
786,400
Avg. Vol
1,420,091
52-wk High
¥2,134
52-wk Low
¥1,397

Latest Key Developments (Source: Significant Developments)

Sunovion Receives FDA Approval for Lonhala Magnair Inhalation Solution to Treat COPD
Tuesday, 5 Dec 2017 08:48pm EST 

Dec 5 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>::SUNOVION RECEIVES FDA APPROVAL FOR LONHALA MAGNAIR INHALATION SOLUTION TO TREAT COPD.SUNOVION EXPECTS LONHALA MAGNAIR TO BE AVAILABLE IN U.S. PHARMACIES IN EARLY 2018.SUNOVION RECEIVES FDA APPROVAL FOR LONHALA MAGNAIR INHALATION SOLUTION TO TREAT COPD.  Full Article

Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda (Lurasidone Hydrochloride) in Europe
Tuesday, 21 Nov 2017 02:32am EST 

Nov 21 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says it and Angelini S.p.A announced today that the companies have formed a partnership with the goal to expand availability in Europe of Latuda®, an atypical antipsychotic which was created by the co .Under the terms of the agreement, Sunovion Pharmaceuticals Europe Ltd., a subsidiary company of Sumitomo Dainippon Pharma Group, has granted Angelini exclusive commercialization rights for LATUDA in 29 European countries and in Turkey.  Full Article

Sumitomo Dainippon Pharma and Poxel announce strategic partnership for development and commercialization of Imeglimin
Monday, 30 Oct 2017 03:06am EDT 

Oct 30 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says it signed an agreement with Poxel SA on Oct. 30, for the development and commercialization of Imeglimin, an investigational therapeutic agent for type 2 diabetes, in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries.Under the Agreement, Poxel SA is entitled to receive an upfront payment of approximately 4.75 billion yen and future potential development milestone payments of up to 2.75 billion yen .  Full Article

Poxel and Sumitomo Dainippon Pharma in partnership to develop and sell Imeglimin in Asia
Monday, 30 Oct 2017 02:30am EDT 

Oct 30 (Reuters) - POXEL SA ::SUMITOMO DAINIPPON PHARMA AND POXEL ANNOUNCE STRATEGIC PARTNERSHIP FOR DEVELOPMENT AND COMMERCIALIZATION OF IMEGLIMIN, AN INVESTIGATIONAL THERAPEUTIC AGENT FOR TYPE 2 DIABETES, IN JAPAN, CHINA AND ELEVEN OTHER ASIAN COUNTRIES.‍POXEL AND SUMITOMO DAINIPPON PHARMA TO JOINTLY DEVELOP IMEGLIMIN FOR TREATMENT OF TYPE 2 DIABETES IN JAPAN,​.‍SUMITOMO DAINIPPON PHARMA ASSUMES PHASE 3 AND COMMERCIALIZATION COSTS​.‍POXEL RECEIVES AN UPFRONT PAYMENT OF ¥4.75 BILLION (APPROXIMATELY EUR 36 MILLION, $42 MILLION)​.‍SUMITOMO DAINIPPON PHARMA SOLELY RESPONSIBLE FOR IMEGLIMIN IN CHINA, SOUTH KOREA, TAIWAN AND 9 OTHER SOUTHEAST ASIAN COUNTRIES​.‍PHASE 3 PROGRAM FOR IMEGLIMIN IN JAPAN ON TRACK TO BE INITIATED IN Q4 OF CY 2017​.‍RECEIVES FUTURE POTENTIAL DEVELOPMENT MILESTONE PAYMENTS AND SALES-BASED PAYMENTS OF UP TO ¥29.25 BILLION​.  Full Article

Kitasato Institute and Sumitomo Dainippon Pharma signs joint drug discovery research agreement
Tuesday, 24 Oct 2017 04:22am EDT 

Oct 24 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says it and the Kitasato Institute have signed a joint drug discovery research agreement for infections caused by bacteria with antimicrobial resistance (AMR).  Full Article

R&I affirms Sumitomo Dainippon Pharma's rating at "A" and announces stable outlook -R&I
Tuesday, 3 Oct 2017 05:19am EDT 

Oct 3(Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A" -R&I.Rating outlook stable -R&I.  Full Article

Sumitomo Dainippon Pharma to offer early-retirement program
Wednesday, 27 Sep 2017 03:10am EDT 

Sept 27 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:* Says it will offer an early-retirement program to employees, who are above 45 years old and continuous service of above 5 years as of March 31, 2018, and employees is members of manufacturing division as of Sept. 1, 2016 .* Offering period from Nov. 15 to Dec. 15.* Says the employees who take up the offer will retire on March 31, 2018.* The company will provide retirement payment and outplacement support to the retiring employees .  Full Article

Sunovion submits new drug application for dasotraline to the FDA for the treatment of patients with ADHD
Thursday, 31 Aug 2017 08:00am EDT 

Aug 31 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Sunovion submits new drug application for dasotraline to the FDA for the treatment of patients with ADHD.‍Sunovion Pharmaceuticals Inc - submitted NDA to U.S. FDA for dasotraline for treatment of children, adolescents and adults with ADHD​.  Full Article

Sunovion’s Latuda receives Health Canada approval to treat adolescents with schizophrenia
Friday, 21 Jul 2017 12:10pm EDT 

July 21 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Sunovion’s Latuda® (lurasidone HCI) receives Health Canada approval to treat adolescents with schizophrenia.Sunovion's Latuda receives Health Canada approval to treat adolescents with schizophrenia.  Full Article

Sumitomo Dainippon Pharma unit Sunovion announces FDA acceptance for review of new drug application resubmission for SUN-101
Sunday, 2 Jul 2017 11:24pm EDT 

July 3(Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says its U.S.-based unit Sunovion Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the New Drug Application for SUN-101/eFlow® (glycopyrrolate) for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).  Full Article